Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. CYTO Peers
See (CYTO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CYTO | $0.30 | +0.00% | 1.1M | 0.16 | $1.82 | N/A |
| VRTX | $459.62 | +0.57% | 118B | -119.69 | -$3.84 | N/A |
| REGN | $547.36 | -0.07% | 58.1B | 13.91 | $39.35 | +0.16% |
| ALNY | $331.91 | +0.65% | 43.3B | -157.30 | -$2.11 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $543.48 | -0.30% | 33.2B | 33.16 | $16.39 | N/A |
| BNTX | $110.00 | +1.61% | 26.4B | -30.05 | -$3.66 | N/A |
| RPRX | $36.37 | +0.50% | 20.5B | 14.84 | $2.45 | +2.36% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
CYTO vs VRTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, VRTX has a market cap of 118B. Regarding current trading prices, CYTO is priced at $0.30, while VRTX trades at $459.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas VRTX's P/E ratio is -119.69. In terms of profitability, CYTO's ROE is +7.83%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CYTO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs REGN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, REGN has a market cap of 58.1B. Regarding current trading prices, CYTO is priced at $0.30, while REGN trades at $547.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas REGN's P/E ratio is 13.91. In terms of profitability, CYTO's ROE is +7.83%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CYTO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ALNY Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ALNY has a market cap of 43.3B. Regarding current trading prices, CYTO is priced at $0.30, while ALNY trades at $331.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ALNY's P/E ratio is -157.30. In terms of profitability, CYTO's ROE is +7.83%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, CYTO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs SGEN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CYTO is priced at $0.30, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CYTO's ROE is +7.83%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CYTO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ARGX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ARGX has a market cap of 33.2B. Regarding current trading prices, CYTO is priced at $0.30, while ARGX trades at $543.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ARGX's P/E ratio is 33.16. In terms of profitability, CYTO's ROE is +7.83%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, CYTO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BNTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BNTX has a market cap of 26.4B. Regarding current trading prices, CYTO is priced at $0.30, while BNTX trades at $110.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BNTX's P/E ratio is -30.05. In terms of profitability, CYTO's ROE is +7.83%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CYTO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RPRX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RPRX has a market cap of 20.5B. Regarding current trading prices, CYTO is priced at $0.30, while RPRX trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RPRX's P/E ratio is 14.84. In terms of profitability, CYTO's ROE is +7.83%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CYTO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BGNE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CYTO is priced at $0.30, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CYTO's ROE is +7.83%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CYTO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs DNA-WT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CYTO is priced at $0.30, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CYTO's ROE is +7.83%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CYTO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs SMMT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, SMMT has a market cap of 18.2B. Regarding current trading prices, CYTO is priced at $0.30, while SMMT trades at $24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas SMMT's P/E ratio is -72.21. In terms of profitability, CYTO's ROE is +7.83%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CYTO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs UTHR Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, UTHR has a market cap of 13.3B. Regarding current trading prices, CYTO is priced at $0.30, while UTHR trades at $294.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas UTHR's P/E ratio is 11.74. In terms of profitability, CYTO's ROE is +7.83%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CYTO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs INCY Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, INCY has a market cap of 13.2B. Regarding current trading prices, CYTO is priced at $0.30, while INCY trades at $68.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas INCY's P/E ratio is 342.25. In terms of profitability, CYTO's ROE is +7.83%, compared to INCY's ROE of +0.01%. Regarding short-term risk, CYTO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs KRTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CYTO is priced at $0.30, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CYTO's ROE is +7.83%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CYTO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs EXEL Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, EXEL has a market cap of 12.6B. Regarding current trading prices, CYTO is priced at $0.30, while EXEL trades at $46.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas EXEL's P/E ratio is 21.07. In terms of profitability, CYTO's ROE is +7.83%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, CYTO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs GMAB Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, GMAB has a market cap of 12.6B. Regarding current trading prices, CYTO is priced at $0.30, while GMAB trades at $20.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas GMAB's P/E ratio is 11.94. In terms of profitability, CYTO's ROE is +7.83%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CYTO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MRNA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MRNA has a market cap of 11.8B. Regarding current trading prices, CYTO is priced at $0.30, while MRNA trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MRNA's P/E ratio is -3.49. In terms of profitability, CYTO's ROE is +7.83%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CYTO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BMRN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, CYTO is priced at $0.30, while BMRN trades at $57.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BMRN's P/E ratio is 21.30. In terms of profitability, CYTO's ROE is +7.83%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CYTO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ASND Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ASND has a market cap of 10.5B. Regarding current trading prices, CYTO is priced at $0.30, while ASND trades at $174.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ASND's P/E ratio is -26.15. In terms of profitability, CYTO's ROE is +7.83%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CYTO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RXDX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CYTO is priced at $0.30, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CYTO's ROE is +7.83%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CYTO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs IMGN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CYTO is priced at $0.30, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CYTO's ROE is +7.83%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, CYTO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BBIO Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BBIO has a market cap of 8.4B. Regarding current trading prices, CYTO is priced at $0.30, while BBIO trades at $43.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BBIO's P/E ratio is -12.36. In terms of profitability, CYTO's ROE is +7.83%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CYTO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs TECH Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, CYTO is priced at $0.30, while TECH trades at $53.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas TECH's P/E ratio is 64.02. In terms of profitability, CYTO's ROE is +7.83%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CYTO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BPMC Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, CYTO is priced at $0.30, while BPMC trades at $128.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BPMC's P/E ratio is -51.34. In terms of profitability, CYTO's ROE is +7.83%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CYTO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CERE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CYTO is priced at $0.30, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CERE's P/E ratio is -16.47. In terms of profitability, CYTO's ROE is +7.83%, compared to CERE's ROE of -0.43%. Regarding short-term risk, CYTO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ROIVW Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, CYTO is priced at $0.30, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CYTO's ROE is +7.83%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, CYTO is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs VRNA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, VRNA has a market cap of 7.8B. Regarding current trading prices, CYTO is priced at $0.30, while VRNA trades at $91.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas VRNA's P/E ratio is -45.76. In terms of profitability, CYTO's ROE is +7.83%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CYTO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CORT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CORT has a market cap of 7.7B. Regarding current trading prices, CYTO is priced at $0.30, while CORT trades at $72.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CORT's P/E ratio is 62.84. In terms of profitability, CYTO's ROE is +7.83%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CYTO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ROIV Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ROIV has a market cap of 7.5B. Regarding current trading prices, CYTO is priced at $0.30, while ROIV trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ROIV's P/E ratio is -14.65. In terms of profitability, CYTO's ROE is +7.83%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, CYTO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RVMD Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RVMD has a market cap of 7.1B. Regarding current trading prices, CYTO is priced at $0.30, while RVMD trades at $37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RVMD's P/E ratio is -9.44. In terms of profitability, CYTO's ROE is +7.83%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CYTO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs AMRN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, AMRN has a market cap of 6.9B. Regarding current trading prices, CYTO is priced at $0.30, while AMRN trades at $16.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas AMRN's P/E ratio is -3.80. In terms of profitability, CYTO's ROE is +7.83%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, CYTO is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs IONS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, IONS has a market cap of 6.8B. Regarding current trading prices, CYTO is priced at $0.30, while IONS trades at $43.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas IONS's P/E ratio is -14.38. In terms of profitability, CYTO's ROE is +7.83%, compared to IONS's ROE of -0.92%. Regarding short-term risk, CYTO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs HALO Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, HALO has a market cap of 6.7B. Regarding current trading prices, CYTO is priced at $0.30, while HALO trades at $54.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas HALO's P/E ratio is 14.36. In terms of profitability, CYTO's ROE is +7.83%, compared to HALO's ROE of +1.22%. Regarding short-term risk, CYTO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MDGL Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MDGL has a market cap of 6.6B. Regarding current trading prices, CYTO is priced at $0.30, while MDGL trades at $298.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MDGL's P/E ratio is -16.76. In terms of profitability, CYTO's ROE is +7.83%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CYTO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs JAZZ Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, JAZZ has a market cap of 6.6B. Regarding current trading prices, CYTO is priced at $0.30, while JAZZ trades at $109.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas JAZZ's P/E ratio is 14.87. In terms of profitability, CYTO's ROE is +7.83%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CYTO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RETA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CYTO is priced at $0.30, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RETA's P/E ratio is -66.29. In terms of profitability, CYTO's ROE is +7.83%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CYTO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs TGTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, CYTO is priced at $0.30, while TGTX trades at $36.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas TGTX's P/E ratio is 146.88. In terms of profitability, CYTO's ROE is +7.83%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CYTO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ABCM Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CYTO is priced at $0.30, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CYTO's ROE is +7.83%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CYTO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ISEE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CYTO is priced at $0.30, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CYTO's ROE is +7.83%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CYTO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs TLX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, TLX has a market cap of 5.4B. Regarding current trading prices, CYTO is priced at $0.30, while TLX trades at $16.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas TLX's P/E ratio is 178.56. In terms of profitability, CYTO's ROE is +7.83%, compared to TLX's ROE of +0.14%. Regarding short-term risk, CYTO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs NUVL Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, NUVL has a market cap of 5.3B. Regarding current trading prices, CYTO is priced at $0.30, while NUVL trades at $80.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas NUVL's P/E ratio is -18.21. In terms of profitability, CYTO's ROE is +7.83%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CYTO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs AXSM Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, CYTO is priced at $0.30, while AXSM trades at $105.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas AXSM's P/E ratio is -18.27. In terms of profitability, CYTO's ROE is +7.83%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CYTO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ALKS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, CYTO is priced at $0.30, while ALKS trades at $28.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ALKS's P/E ratio is 13.74. In terms of profitability, CYTO's ROE is +7.83%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, CYTO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CRSP Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, CYTO is priced at $0.30, while CRSP trades at $52.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CRSP's P/E ratio is -11.62. In terms of profitability, CYTO's ROE is +7.83%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CYTO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ALPN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CYTO is priced at $0.30, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CYTO's ROE is +7.83%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, CYTO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs SLNO Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, CYTO is priced at $0.30, while SLNO trades at $86.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas SLNO's P/E ratio is -18.28. In terms of profitability, CYTO's ROE is +7.83%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CYTO is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ADMA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, CYTO is priced at $0.30, while ADMA trades at $18.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ADMA's P/E ratio is 21.76. In terms of profitability, CYTO's ROE is +7.83%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CYTO is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs PCVX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, CYTO is priced at $0.30, while PCVX trades at $33.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas PCVX's P/E ratio is -8.33. In terms of profitability, CYTO's ROE is +7.83%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CYTO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs OPT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CYTO is priced at $0.30, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas OPT's P/E ratio is -1.52. In terms of profitability, CYTO's ROE is +7.83%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CYTO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RYTM Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RYTM has a market cap of 4.2B. Regarding current trading prices, CYTO is priced at $0.30, while RYTM trades at $65.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RYTM's P/E ratio is -23.49. In terms of profitability, CYTO's ROE is +7.83%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CYTO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CYTK Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, CYTO is priced at $0.30, while CYTK trades at $34.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CYTK's P/E ratio is -6.55. In terms of profitability, CYTO's ROE is +7.83%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CYTO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs KRYS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, KRYS has a market cap of 4.1B. Regarding current trading prices, CYTO is priced at $0.30, while KRYS trades at $143.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas KRYS's P/E ratio is 34.31. In terms of profitability, CYTO's ROE is +7.83%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CYTO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs AKRO Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, CYTO is priced at $0.30, while AKRO trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas AKRO's P/E ratio is -13.81. In terms of profitability, CYTO's ROE is +7.83%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CYTO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MRTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CYTO is priced at $0.30, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CYTO's ROE is +7.83%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CYTO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ZLAB Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ZLAB has a market cap of 4B. Regarding current trading prices, CYTO is priced at $0.30, while ZLAB trades at $36.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ZLAB's P/E ratio is -14.56. In terms of profitability, CYTO's ROE is +7.83%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, CYTO is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MRUS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MRUS has a market cap of 4B. Regarding current trading prices, CYTO is priced at $0.30, while MRUS trades at $53.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MRUS's P/E ratio is -12.94. In terms of profitability, CYTO's ROE is +7.83%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CYTO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs PTCT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, CYTO is priced at $0.30, while PTCT trades at $49.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas PTCT's P/E ratio is 7.54. In terms of profitability, CYTO's ROE is +7.83%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CYTO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RARE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RARE has a market cap of 3.8B. Regarding current trading prices, CYTO is priced at $0.30, while RARE trades at $39.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RARE's P/E ratio is -6.85. In terms of profitability, CYTO's ROE is +7.83%, compared to RARE's ROE of -1.86%. Regarding short-term risk, CYTO is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RYZB Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CYTO is priced at $0.30, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CYTO's ROE is +7.83%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CYTO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CBAY Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CYTO is priced at $0.30, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CYTO's ROE is +7.83%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CYTO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs AAPG Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, AAPG has a market cap of 3.7B. Regarding current trading prices, CYTO is priced at $0.30, while AAPG trades at $42.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas AAPG's P/E ratio is -57.13. In terms of profitability, CYTO's ROE is +7.83%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, CYTO is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ACLX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ACLX has a market cap of 3.7B. Regarding current trading prices, CYTO is priced at $0.30, while ACLX trades at $67.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ACLX's P/E ratio is -22.46. In terms of profitability, CYTO's ROE is +7.83%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CYTO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs SWTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CYTO is priced at $0.30, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CYTO's ROE is +7.83%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CYTO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RNA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, CYTO is priced at $0.30, while RNA trades at $29.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RNA's P/E ratio is -9.72. In terms of profitability, CYTO's ROE is +7.83%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CYTO is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ACAD Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, CYTO is priced at $0.30, while ACAD trades at $20.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ACAD's P/E ratio is 15.29. In terms of profitability, CYTO's ROE is +7.83%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CYTO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs SRRK Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, CYTO is priced at $0.30, while SRRK trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas SRRK's P/E ratio is -14.11. In terms of profitability, CYTO's ROE is +7.83%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CYTO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs LEGN Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, CYTO is priced at $0.30, while LEGN trades at $35.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas LEGN's P/E ratio is -30.20. In terms of profitability, CYTO's ROE is +7.83%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CYTO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs VKTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, VKTX has a market cap of 3.2B. Regarding current trading prices, CYTO is priced at $0.30, while VKTX trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas VKTX's P/E ratio is -24.30. In terms of profitability, CYTO's ROE is +7.83%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, CYTO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs PTGX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, PTGX has a market cap of 3.2B. Regarding current trading prices, CYTO is priced at $0.30, while PTGX trades at $51.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas PTGX's P/E ratio is 65.45. In terms of profitability, CYTO's ROE is +7.83%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CYTO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MLTX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MLTX has a market cap of 3.1B. Regarding current trading prices, CYTO is priced at $0.30, while MLTX trades at $48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MLTX's P/E ratio is -21.26. In terms of profitability, CYTO's ROE is +7.83%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, CYTO is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MTSR Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MTSR has a market cap of 3.1B. Regarding current trading prices, CYTO is priced at $0.30, while MTSR trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MTSR's P/E ratio is -11.59. In terms of profitability, CYTO's ROE is +7.83%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, CYTO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs KYMR Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, KYMR has a market cap of 2.9B. Regarding current trading prices, CYTO is priced at $0.30, while KYMR trades at $44.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas KYMR's P/E ratio is -14.40. In terms of profitability, CYTO's ROE is +7.83%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CYTO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs IMVT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, CYTO is priced at $0.30, while IMVT trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas IMVT's P/E ratio is -6.21. In terms of profitability, CYTO's ROE is +7.83%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, CYTO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MORF Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CYTO is priced at $0.30, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MORF's P/E ratio is -14.88. In terms of profitability, CYTO's ROE is +7.83%, compared to MORF's ROE of -0.22%. Regarding short-term risk, CYTO is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MOR Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CYTO is priced at $0.30, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MOR's P/E ratio is -12.64. In terms of profitability, CYTO's ROE is +7.83%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CYTO is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs APGE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, APGE has a market cap of 2.8B. Regarding current trading prices, CYTO is priced at $0.30, while APGE trades at $47.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas APGE's P/E ratio is -13.15. In terms of profitability, CYTO's ROE is +7.83%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CYTO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CRNX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, CYTO is priced at $0.30, while CRNX trades at $29.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CRNX's P/E ratio is -7.84. In terms of profitability, CYTO's ROE is +7.83%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CYTO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs KDNY Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, CYTO is priced at $0.30, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CYTO's ROE is +7.83%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CYTO is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MYOV Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, CYTO is priced at $0.30, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CYTO's ROE is +7.83%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CYTO is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CPRX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, CYTO is priced at $0.30, while CPRX trades at $21.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CPRX's P/E ratio is 13.67. In terms of profitability, CYTO's ROE is +7.83%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CYTO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs XENE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, CYTO is priced at $0.30, while XENE trades at $33.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas XENE's P/E ratio is -10.33. In terms of profitability, CYTO's ROE is +7.83%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CYTO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs MIRM Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, CYTO is priced at $0.30, while MIRM trades at $50.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas MIRM's P/E ratio is -31.24. In terms of profitability, CYTO's ROE is +7.83%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CYTO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs IBRX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, CYTO is priced at $0.30, while IBRX trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas IBRX's P/E ratio is -4.77. In terms of profitability, CYTO's ROE is +7.83%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CYTO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs PRVB Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, CYTO is priced at $0.30, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CYTO's ROE is +7.83%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CYTO is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs LBPH Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, CYTO is priced at $0.30, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CYTO's ROE is +7.83%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CYTO is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs ARWR Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, CYTO is priced at $0.30, while ARWR trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas ARWR's P/E ratio is -13.54. In terms of profitability, CYTO's ROE is +7.83%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, CYTO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs APLS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, APLS has a market cap of 2.3B. Regarding current trading prices, CYTO is priced at $0.30, while APLS trades at $18.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas APLS's P/E ratio is -10.14. In terms of profitability, CYTO's ROE is +7.83%, compared to APLS's ROE of -1.00%. Regarding short-term risk, CYTO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs DICE Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, CYTO is priced at $0.30, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas DICE's P/E ratio is -21.91. In terms of profitability, CYTO's ROE is +7.83%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CYTO is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs NAMS Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, NAMS has a market cap of 2.2B. Regarding current trading prices, CYTO is priced at $0.30, while NAMS trades at $19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas NAMS's P/E ratio is -10.79. In terms of profitability, CYTO's ROE is +7.83%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, CYTO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs LGND Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, CYTO is priced at $0.30, while LGND trades at $114.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas LGND's P/E ratio is -15.72. In terms of profitability, CYTO's ROE is +7.83%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CYTO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs VCYT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, VCYT has a market cap of 2.2B. Regarding current trading prices, CYTO is priced at $0.30, while VCYT trades at $27.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas VCYT's P/E ratio is 65.50. In terms of profitability, CYTO's ROE is +7.83%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, CYTO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CALT Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CALT's P/E ratio is -22.73. In terms of profitability, CYTO's ROE is +7.83%, compared to CALT's ROE of -1.67%. Regarding short-term risk, CYTO is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs DNLI Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while DNLI trades at $14.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas DNLI's P/E ratio is -5.50. In terms of profitability, CYTO's ROE is +7.83%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, CYTO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs RXRX Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, RXRX has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while RXRX trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas RXRX's P/E ratio is -2.93. In terms of profitability, CYTO's ROE is +7.83%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, CYTO is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs VCEL Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, VCEL has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while VCEL trades at $41.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas VCEL's P/E ratio is 834.80. In terms of profitability, CYTO's ROE is +7.83%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, CYTO is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs AGIO Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while AGIO trades at $36.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas AGIO's P/E ratio is 3.13. In terms of profitability, CYTO's ROE is +7.83%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, CYTO is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs CGON Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, CYTO is priced at $0.30, while CGON trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas CGON's P/E ratio is -17.93. In terms of profitability, CYTO's ROE is +7.83%, compared to CGON's ROE of -0.17%. Regarding short-term risk, CYTO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs KNSA Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, CYTO is priced at $0.30, while KNSA trades at $27.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas KNSA's P/E ratio is -116.17. In terms of profitability, CYTO's ROE is +7.83%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, CYTO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs BEAM Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, BEAM has a market cap of 2B. Regarding current trading prices, CYTO is priced at $0.30, while BEAM trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas BEAM's P/E ratio is -4.34. In terms of profitability, CYTO's ROE is +7.83%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, CYTO is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.
CYTO vs NAMSW Comparison
CYTO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CYTO stands at 1.1M. In comparison, NAMSW has a market cap of 2B. Regarding current trading prices, CYTO is priced at $0.30, while NAMSW trades at $9.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CYTO currently has a P/E ratio of 0.16, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CYTO's ROE is +7.83%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, CYTO is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CYTO.